Adicet Bio’s ADI-270 Gets FDA Fast Track for Cancer Therapy

Adicet Bio (ACET) has shared an announcement.

Adicet Bio, Inc. has announced that their drug ADI-270 has been granted Fast Track Designation by the FDA for treating metastatic/advanced clear cell renal cell carcinoma. This milestone, which may be of interest to investors watching the biotech sector, signifies the company’s potential to expedite the development and review process for this promising cancer therapy.

See more data about ACET stock on TipRanks’ Stock Analysis page.